دورية أكاديمية

FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila.

التفاصيل البيبلوغرافية
العنوان: FRA16D common chromosomal fragile site oxido-reductase (FOR/WWOX) protects against the effects of ionizing radiation in Drosophila.
المؤلفون: O'Keefe, Louise V.1, Yinghong Liu1, Perkins, Alison1, Dayan, Sonia1, Saint, Robert1,2,3, Richards, Robert I.1,2 robert.richards@adelaide.edu.au
المصدر: Oncogene. 9/29/2005, Vol. 24 Issue 43, p6590-6596. 7p. 1 Color Photograph, 1 Diagram, 2 Charts, 1 Graph.
مصطلحات موضوعية: *CANCER, *MULTIPLE myeloma, *GENE expression, *IONIZING radiation, *DROSOPHILA, *CHROMOSOMES, *MUTAGENESIS
مستخلص: Fragile sites are chromosomal structures that have been proposed to have a determining role in cancer-associated DNA instability. The human WWOX gene spans the FRA16D chromosomal fragile site, the common minimal region of homozygous deletion found in adenocarcinomas and three out of five translocation breakpoints in multiple myeloma. Transcripts from the alternatively spliced WWOX gene encode proteins with common N-terminal WW domains and variable homology to the oxidoreductase family of proteins. In this study, the Drosophila orthologue of the WWOX gene was identified and subjected to mutagenesis via homologous recombination. The resultant DmWWOX1 mutants were viable but exhibited an increased sensitivity to ionizing radiation. This radiation sensitivity was rescued by reintroduction and expression of either the wild-type Drosophila or human WWOX genes. Thus, the protective function of DmWWOX in response to irradiation in Drosophila is conserved with human WWOX (hWWOX). This is consistent with a protective role for hWWOX where aberrant expression, as a result of breakage at the associated fragile site, could contribute directly to cancer progression.Oncogene (2005) 24, 6590–6596. doi:10.1038/sj.onc.1208806; published online 20 June 2005 [ABSTRACT FROM AUTHOR]
قاعدة البيانات: Academic Search Index
الوصف
تدمد:09509232
DOI:10.1038/sj.onc.1208806